Continued vorapaxar versus withdrawed clopidogrel both on top of low dose aspirin in patients undergoing heart surgery: A call for randomized trial.
暂无分享,去创建一个
V. Serebruany | M. Cattaneo | T. Marciniak | Moo-Hyun Kim | E. Golukhova | M. Bekbossynova | Y. Pya | Makhabbat Bekbossynova
[1] Sunil V. Rao,et al. Arterial access site and outcomes in patients undergoing percutaneous coronary intervention with and without vorapaxar , 2016, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.
[2] C. Held,et al. Efficacy and Safety of Vorapaxar in Non–ST‐Segment Elevation Acute Coronary Syndrome Patients Undergoing Noncardiac Surgery , 2015, Journal of the American Heart Association.
[3] R. Khouzam,et al. Dual Antiplatelet Therapy After Coronary Artery Bypass Grafting in the Setting of Acute Coronary Syndrome. , 2015, The American journal of cardiology.
[4] M. Movahed,et al. A Novel Inhibitor of Protease-activated Receptor 1: A Review of Chemical Structure and Mode of Action. , 2015, Reviews in cardiovascular medicine.
[5] F. Eckstein,et al. Prasugrel Increases the Need for Platelet Transfusions and Surgical Reexploration Rates Compared with Clopidogrel in Coronary Artery Bypass Surgery , 2014, Thoracic and Cardiovascular Surgeon.
[6] K. Filion,et al. Coronary artery bypass graft surgery versus percutaneous coronary intervention with first-generation drug-eluting stents: a meta-analysis of randomized controlled trials. , 2014, JACC. Cardiovascular interventions.
[7] C. Held,et al. Vorapaxar in acute coronary syndrome patients undergoing coronary artery bypass graft surgery: subgroup analysis from the TRACER trial (Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome). , 2014, Journal of the American College of Cardiology.
[8] M. Akay,et al. Coronary artery bypass grafting vs percutaneous coronary intervention and long-term mortality and morbidity in multivessel disease: meta-analysis of randomized clinical trials of the arterial grafting and stenting era. , 2014, JAMA internal medicine.
[9] D. Steinbrüchel,et al. Off-Pump Versus On-Pump Coronary Artery Bypass Grafting , 2014, Current Cardiology Reports.
[10] Xiaochun Ma,et al. Safety and Efficacy Outcomes of Preoperative Aspirin in Patients Undergoing Coronary Artery Bypass Grafting , 2014, Journal of cardiovascular pharmacology and therapeutics.
[11] V. Fuster,et al. Comparison of coronary artery bypass surgery and percutaneous coronary intervention in patients with diabetes: a meta-analysis of randomised controlled trials. , 2013, The lancet. Diabetes & endocrinology.
[12] C. Held,et al. Effect of ticagrelor on the outcomes of patients with prior coronary artery bypass graft surgery: insights from the PLATelet inhibition and patient outcomes (PLATO) trial. , 2013, American heart journal.
[13] P. Erwin,et al. Dual Anti‐platelet Therapy After Coronary Artery Bypass Grafting: Is There Any Benefit? A Systematic Review and Meta‐Analysis , 2013, Journal of cardiac surgery.
[14] Adil A M Al-Lawati,et al. Continuing Aspirin Causes Higher Drainage Even under Full Protection with Antifibrinolytics , 2013, Thoracic and Cardiovascular Surgeon.
[15] Howard K. Song,et al. 2012 update to the Society of Thoracic Surgeons guideline on use of antiplatelet drugs in patients having cardiac and noncardiac operations. , 2012, The Annals of thoracic surgery.
[16] Marc P. Bonaca,et al. Vorapaxar in the secondary prevention of atherothrombotic events. , 2012, The New England journal of medicine.
[17] D. Steinbrüchel,et al. Hypercoagulability in patients undergoing coronary artery bypass grafting: prevalence, patient characteristics and postoperative outcome. , 2012, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.
[18] Giuseppe Ambrosio,et al. Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. , 2012, The New England journal of medicine.
[19] T. Athanasiou,et al. Safety of clopidogrel being continued until the time of coronary artery bypass grafting in patients with acute coronary syndrome: a meta-analysis of 34 studies. , 2011, European heart journal.
[20] Michael A. Burke,et al. Early clopidogrel use in non-ST elevation acute coronary syndrome and subsequent coronary artery bypass grafting. , 2011, American heart journal.
[21] W. Saggau,et al. Functional evaluation of platelet aspirin resistance after on-pump coronary bypass grafting using multiple aggregation tests. , 2011, The Thoracic and cardiovascular surgeon.
[22] J. Segal,et al. Effects of aspirin responsiveness and platelet reactivity on early vein graft thrombosis after coronary artery bypass graft surgery. , 2011, Journal of the American College of Cardiology.
[23] R. Körfer,et al. Prevalent platelet dysfunction in patients with aortic valve disease. , 2008, The Journal of heart valve disease.